Today's Research on Celsion, Zogenix, Actavis, and Avanir Pharma PR Newswire LONDON, April 10, 2013 LONDON, April 10, 2013 /PRNewswire/ -- One of the major trends to emerge in the healthcare industry in the last year has been the expiration of patents on several blockbuster drugs. This had led to increasing competition from generic drug companies such as Actavis Inc. (NYSE: ACT) and Avanir Pharmaceuticals Inc. (NASDAQ: AVNR). For major drug manufacturers such as Zogenix Inc. (NASDAQ: ZGNX), the key will be to continue to boost their product pipeline. Major drug manufacturers are also likely to collaborate with biotechnology companies such as Celsion Corporation (NASDAQ: CLSN) that are developing or have developed potential blockbuster drugs. On Tuesday, healthcare stocks ended on a mixed note even as the broad market posted significant gains. StockCall professionals have completed their technical analysis on CLSN, ZGNX, ACT, and AVNR and these free reports are accessible by registering at http://www.stockcall.com/research Shares of Celsion Corporation edged higher yesterday; however, the gains were limited. The stock touched an intra-day high of $1 before finishing the day 0.41% higher at $0.974 on volume of 523,658. Despite the gains on Tuesday, Celsion's shares have fallen more than 4.50% in the last three trading sessions. Year-to-date, the stock has lost more than 88% of its value. Most of the losses came in February when the stock saw a steep decline. In the last one month, shares of CLSN have traded sideways, struggling to break through $1 level. Sign up for the free technical research on CLSN at http://www.StockCall.com/CLSN041013.pdf Shares of Zogenix Inc. saw a sharp decline in trading on Tuesday. The stock ended the day 2.52% lower at $1.55 on volume of 515,540. The stock has now fallen more than 13.40% in the last three trading sessions. The major drug maker's shares have fallen sharply after the stock failed to break through $2 resistance level. The stock recently slipped below $1.60 support level, and also its 50-day moving average. This suggests that market sentiment is currently bearish on the stock. The downbeat trend is further confirmed by the stock's MACD chart. Be sure to read our latest technical research on ZGNX by registering at http://www.StockCall.com/ZGNX041013.pdf Actavis Inc.'s shares ended marginally lower on Tuesday. The stock touched a 52-week high of $98.46 earlier in the day; however, it failed to hold onto its gains. Actavis' shares ended the day 0.66% lower at $97.71 on volume of 1.10 million. Despite the losses yesterday, the generic drug maker's shares are still up nearly 2% in the last three trading sessions. The stock has had an excellent run so far in 2013, gaining more than 13.60%. The company's shares have seen a series of highs since last month, which is a bullish signal. Sign up and read the complimentary report on ACT at http://www.StockCall.com/ACT041013.pdf Avanir Pharmaceuticals Inc.'s shares were among the major gainers in the healthcare sector on Tuesday. The stock closed 2.65% higher at $2.71 on volume of 594,199 after touching an intra-day high of $2.77. Avanir's shares are currently trading more than 33% below their 52-week high. The stock bounced back yesterday after seeing a series of lows in the past two weeks. Shares of this generic drug maker are still trading well below their 50-day and 200-day moving averages, which is a bearish signal. The negative trend is further confirmed by the stock's MACD chart. The free report on AVNR can be downloaded by signing up now at http://www.StockCall.com/AVNR041013.pdf About StockCall.com StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at http://www.stockcall.com SOURCE StockCall.com Contact: Contact Person: William T. Knight, Email: firstname.lastname@example.org, Contact Number: +1(646)396-9857 (9:00 am EST - 01:30 pm EST)
Today's Research on Celsion, Zogenix, Actavis, and Avanir Pharma
Press spacebar to pause and continue. Press esc to stop.